Skin cancer vaccine BLA submitted by June 30, 2027?
BUY YES
- Cost
- 79.0¢
- Implied chance
- 79.0%
- Return if right
- 26.6%
- Spread cost
- 3%
If you put in $100
You get 126.6 shares at 79.0¢ each.
YES wins: $126.58 back, a profit of $26.58. YES loses: $0.00, and the whole $100 is gone.
The gap between buyers and sellers takes $0.81 of that profit. Without it you would make $27.39.
Assumes the whole order fills at this price. A large order eats into the book and averages worse.
Buy YES on Polymarket
BUY NO
- Cost
- 22.0¢
- Implied chance
- 22.0%
- Return if right
- 354.5%
- Spread cost
- 3%
If you put in $100
You get 454.5 shares at 22.0¢ each.
NO wins: $454.55 back, a profit of $354.55. NO loses: $0.00, and the whole $100 is gone.
The gap between buyers and sellers takes $10.57 of that profit. Without it you would make $365.12.
Assumes the whole order fills at this price. A large order eats into the book and averages worse.
Buy NO on Polymarket
Latest news
headlines link to their publishersNo recent headlines matched this market. We only show an article when the names in the question appear in its headline, so a very local or very new market often has nothing. Showing nothing is deliberate: an unrelated story here would read like evidence about the price.
Headlines are matched on the names in “Skin cancer vaccine BLA submitted by June 30, 2027?”. Nobody checks them by hand, so one may not be relevant. They also say nothing about whether the price has already moved on this news.
How this market resolves
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.